Markers of Bone Resorption in Breast Cancer Patients
Author Information
Author(s): JJ Body, JC Dumon, E Gineyts, PD Delmas
Primary Institution: Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Hypothesis
Can new markers of bone turnover provide better monitoring of bone resorption in breast cancer patients undergoing bisphosphonate therapy?
Conclusion
New markers of bone resorption are more frequently elevated than traditional markers in breast cancer patients with bone metastases, and they show significant decreases after bisphosphonate therapy.
Supporting Evidence
- Markers of bone resorption were elevated in 100% of patients for CrossLaps and D-Pyr.
- All parameters, except phosphaturia, fell significantly after pamidronate therapy.
- Correlations between the new markers of bone resorption were statistically significant.
Takeaway
This study looked at how well new tests can measure bone damage in breast cancer patients and found that these tests work better than older ones after treatment.
Methodology
The study involved 19 ambulatory patients with advanced breast cancer who received a single infusion of pamidronate and were monitored for changes in various bone resorption markers over 8 weeks.
Limitations
The study had a small sample size and did not include patients receiving other systemic therapies.
Participant Demographics
All participants were post-menopausal women with a median age of 60 years.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website